

Richard B Lanman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1496030/publications.pdf>

Version: 2024-02-01

153
papers

11,740
citations

26610

56
h-index

29127

104
g-index

159
all docs

159
docs citations

159
times ranked

13737
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Nonâ€“Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 72-81.	1.1	17
2	Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With <i>IDH</i>-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. <i>JCO Precision Oncology</i>, 2022, 6, e2100197.</i>	1.5	10
3	Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. <i>Molecular Oncology</i> , 2021, 15, 67-79.	2.1	28
4	Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Nonâ€“Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 93-102.	1.5	31
5	Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). <i>Journal of Clinical Oncology</i> , 2021, 39, 285-294.	0.8	169
6	Ancient DNA analysis of archaeological specimens extends Chinook salmonâ€™s known historic range to San Francisco Bayâ€™s tributaries and southernmost watershed. <i>PLoS ONE</i> , 2021, 16, e0244470.	1.1	0
7	Genomic profile of advanced breast cancer in circulating tumour DNA. <i>Nature Communications</i> , 2021, 12, 2423.	5.8	54
8	Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 601-609.	0.5	40
9	Western Message Petroglyphs indicate historic beaver presence in a San Francisco Bay Area watershed. <i>California Fish and Wildlife Journal</i> , 2021, 107, 89-98.	0.2	1
10	Co-occurring Alterations in the RASâ€™MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 439-449.	3.2	64
11	Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. <i>European Urology Oncology</i> , 2020, 3, 695-699.	2.6	30
12	Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , 2020, 27, 3259-3267.	0.7	14
13	Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in nonâ€“small cell lung cancer: Analysis of over 8000 cases. <i>Cancer</i> , 2020, 126, 3219-3228.	2.0	106
14	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 821-831.	5.1	243
15	Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1611-1623.	0.5	43
16	Identification of Somatic Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i>, 2020, 26, 4852-4862.</i>	3.2	12
17	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1924-1931.	3.2	50
18	Neurofibromin Is an Estrogen Receptor- β Transcriptional Co-repressor in Breast Cancer. <i>Cancer Cell</i> , 2020, 37, 387-402.e7.	7.7	59

#	ARTICLE	IF	CITATIONS
19	Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion <i>BRCA</i> Mutations among Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2546-2555.	3.2	33
20	Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i> -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 198-213.	7.7	83
21	Alterations in <i>PTEN</i> and <i>ESR1</i> promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , 2020, 1, 382-393.	5.7	96
22	Resistance to <i>TRK</i> inhibition mediated by convergent <i>MAPK</i> pathway activation. <i>Nature Medicine</i> , 2019, 25, 1422-1427.	15.2	144
23	Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. <i>Clinical Cancer Research</i> , 2019, 25, 6107-6118.	3.2	54
24	Therapeutic outcomes in non-small cell lung cancer with <i>BRAF</i> mutations: a single institution, retrospective cohort study. <i>Translational Lung Cancer Research</i> , 2019, 8, 258-267.	1.3	17
25	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. <i>Clinical Cancer Research</i> , 2019, 25, 7035-7045.	3.2	152
26	Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway Aberrations. <i>Clinical Cancer Research</i> , 2019, 25, 5832-5842.	3.2	64
27	Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations. <i>Clinical Cancer Research</i> , 2019, 25, 6119-6126.	3.2	28
28	Identification of osimertinib-resistant <i>EGFR</i> L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort. <i>Experimental Hematology and Oncology</i> , 2019, 8, 24.	2.0	14
29	Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic <i>HER2</i> -Positive Breast Cancer: NSABP Foundation Trial FB-10. <i>Journal of Clinical Oncology</i> , 2019, 37, 2601-2609.	0.8	50
30	Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 7098-7112.	3.2	142
31	<i>BRAF</i> Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. <i>Cancers</i> , 2019, 11, 1381.	1.7	44
32	Pan-Cancer Landscape and Analysis of <i>ERBB2</i> Mutations Identifies Pozotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. <i>Cancer Cell</i> , 2019, 36, 444-457.e7.	7.7	145
33	Identification of Actionable Fusions as an Anti- <i>EGFR</i> Resistance Mechanism Using a Circulating Tumor DNA Assay. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	1.5	14
34	Treatment with Next-Generation <i>ALK</i> Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity. <i>Clinical Cancer Research</i> , 2019, 25, 6662-6670.	3.2	122
35	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. <i>Lung Cancer</i> , 2019, 134, 72-78.	0.9	24
36	Revisiting Epidermal Growth Factor Receptor (<i>EGFR</i>) Amplification as a Target for Anti- <i>EGFR</i> Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	37

#	ARTICLE	IF	CITATIONS
37	Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. <i>JCO Precision Oncology</i> , 2019, 3, 1-16.	1.5	30
38	Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4691-4700.	3.2	401
39	Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort. <i>Frontiers in Oncology</i> , 2019, 9, 212.	1.3	20
40	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. <i>Nature Communications</i> , 2019, 10, 1373.	5.8	252
41	Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. <i>CNS Oncology</i> , 2019, 8, CNS34.	1.2	112
42	Plasma HER2 (<i>ERBB2</i>) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3046-3053.	3.2	112
43	Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 816-824.	0.5	78
44	Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	1.5	6
45	Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1852-1862.	1.9	22
46	Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 130.	6.9	64
47	Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	20
48	Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	37
49	<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i> -Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2019, 9, 199-209.	7.7	115
50	Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019, 125, 1459-1469.	2.0	38
51	Combined Blockade of Activating <i>ERBB2</i> Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 277-289.	3.2	74
52	Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations. <i>Clinical Lung Cancer</i> , 2019, 20, 30-36.e3.	1.1	37
53	Abstract 1675: Analytical validation of MSI High detection with GuardantOMNI. , 2019, , .		0
54	Abstract 435: Cell-free circulating tumor DNA (ctDNA) detects somatic copy number loss in homologous recombination repair genes. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
55	Abstract 3769: Detection of allele specific loss of heterozygosity in 70,000 patients with ctDNA. , 2019, , .		0
56	Abstract LB-235: COLOMATE: Colorectal cancer and liquid biopsy screening protocol for molecularly assigned therapy. Cancer Research, 2019, 79, LB-235-LB-235.	0.4	2
57	Abstract 450: Novel genomic differences in cell-free circulating tumor DNA (cfDNA) profiles of early versus older onset colorectal cancer (CRC). , 2019, , .		0
58	Abstract LB-118: Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation. Cancer Research, 2019, 79, LB-118-LB-118.	0.4	4
59	Abstract 2509: Analysis of clonal hematopoiesis-associated mutations in the cell-free DNA of advanced cancer patients. Cancer Research, 2019, 79, 2509-2509.	0.4	1
60	Abstract 3404: Landscape and genomic correlates of ctDNA-based tumor mutational burden across six solid tumor types. , 2019, , .		0
61	Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for <i>EGFR</i> -Amplified Gastroesophageal Adenocarcinoma. Cancer Discovery, 2018, 8, 696-713.	7.7	107
62	Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer, 2018, 124, 2115-2124.	2.0	79
63	Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist, 2018, 23, 586-593.	1.9	75
64	Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies. Clinical Cancer Research, 2018, 24, 3539-3549.	3.2	307
65	<i>PIK3CA</i> C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K Inhibitors. Clinical Cancer Research, 2018, 24, 1426-1435.	3.2	27
66	Molecular Landscape of <i>ERBB2/ERBB3</i> Mutated Colorectal Cancer. Journal of the National Cancer Institute, 2018, 110, 1409-1417.	3.0	53
67	Clinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of <i>ALK</i> Inhibitor Resistance in Non-Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 2758-2770.	3.2	143
68	Anaplastic Lymphoma Kinase Mutation (<i>ALK</i> F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib. Clinical Cancer Research, 2018, 24, 2732-2739.	3.2	30
69	JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. Cancer Biology and Therapy, 2018, 19, 664-668.	1.5	4
70	Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile. European Urology, 2018, 73, 308-310.	0.9	12
71	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discovery, 2018, 8, 164-173.	7.7	243
72	Multiplex Gene Profiling of Cell-Free DNA in Patients With Metastatic Melanoma for Monitoring Disease. JCO Precision Oncology, 2018, 2, 1-30.	1.5	13

#	ARTICLE	IF	CITATIONS
73	Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15.	1.5	17
74	Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in <i>BRCA2</i> -Associated Prostate Cancer Resulting From Biallelic <i>BRCA2</i> Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations. <i>JCO Precision Oncology</i> , 2018, 2, 1-8.	1.5	32
75	Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non-Small-Cell Lung Cancer: A Multicenter Case Series. <i>JCO Precision Oncology</i> , 2018, 2, 1-10.	1.5	7
76	Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 3459-3465.	0.8	79
77	Circulating Cell-Free Tumor DNA in the Management of Double Primary Tumors. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	1.5	1
78	Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion. <i>Cancer Discovery</i> , 2018, 8, 1529-1539.	7.7	342
79	Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 305.	1.3	15
80	The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1705-1716.	0.5	38
81	The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 3528-3538.	3.2	288
82	Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival. <i>Annals of Surgical Oncology</i> , 2018, 25, 2400-2408.	0.7	46
83	Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5963-5976.	3.2	63
84	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. <i>Cancer Cell</i> , 2018, 34, 148-162.e7.	7.7	129
85	Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays. <i>JAMA Oncology</i> , 2018, 4, 1429.	3.4	4
86	Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia. <i>Clinical Lung Cancer</i> , 2018, 19, e601-e608.	1.1	8
87	Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor. <i>Clinical Lung Cancer</i> , 2018, 19, 518-530.e7.	1.1	48
88	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. <i>Cancer Discovery</i> , 2018, 8, 1096-1111.	7.7	256
89	Abstract 5603: Analytical validation of a comprehensive 500-gene ctDNA panel designed for immuno-oncology and DNA damage research. , 2018, , .		11
90	Abstract 936: Analysis of cell-free DNA from 32,991 advanced cancers reveals novel co-occurring activating RET alterations and oncogenic signaling pathway aberrations. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
91	Plasma HER2 (ERBB2) copy number to predict response to HER2-targeted therapy in metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 3506-3506.	0.8	8
92	Circulating tumor DNA (ctDNA) landscape and prognostic implications in advanced gastroesophageal adenocarcinoma (GEC).. Journal of Clinical Oncology, 2018, 36, 45-45.	0.8	5
93	Impact of microsatellite instability (MSI) on tumor clonal evolution in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 616-616.	0.8	2
94	Serial monitoring of ctDNA to highlight mutation profiles in colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 641-641.	0.8	2
95	Predictors for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 634-634.	0.8	0
96	Abstract 5533: Cell-free DNA sequencing in ERBB2-mutant breast cancer patients treated with neratinib and fulvestrant: Exploratory analysis from the Phase 2 SUMMIT ‘basket’ trial. , 2018, , .		0
97	Abstract 2848: Radiographic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. , 2018, , .		1
98	Abstract 4272: A novel approach to differentiation of somatic vs. germline variants in liquid biopsies using a betabinomial model. Cancer Research, 2018, 78, 4272-4272.	0.4	8
99	Abstract 3662: Cell-free DNA sequencing demonstrates persistence of nucleic acid-based therapy’s opportunities for detection and monitoring. , 2018, , .		0
100	Abstract 1183: Targeted sequencing of cell-free DNA data enables comprehensive profiling of tumor copy number landscape from blood. , 2018, , .		0
101	Abstract 636: Accounting for processed pseudogene-related artifacts improves specificity of clinical cancer diagnostic sequencing. , 2018, , .		0
102	Abstract 2190: A method for differentiating clonal driver mutations from subclonal emerging resistance mutations in circulating cell-free DNA. , 2018, , .		0
103	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2017, 18, 446-453.	5.1	322
104	An Acquired <i>HER2</i> T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with <i>HER2</i> Mutant-Driven Breast Cancer. Cancer Discovery, 2017, 7, 575-585.	7.7	85
105	Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR -Mutated Lung Cancer. Journal of Thoracic Oncology, 2017, 12, e81-e84.	0.5	41
106	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. European Urology, 2017, 72, 557-564.	0.9	108
107	Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities. Clinical Lung Cancer, 2017, 18, 651-659.	1.1	164
108	Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clinical Cancer Research, 2017, 23, 5101-5111.	3.2	126

#	ARTICLE	IF	CITATIONS
109	Discrimination of Germline <i>EGFR</i> T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 7351-7359.	3.2	74
110	Questions Regarding <i>CD74-ROS1</i> Fusion in NSCLC Detected by Hybrid Capture-Based Tissue Genomic Profiling and ctDNA Assays. <i>Journal of Thoracic Oncology</i> , 2017, 12, e127-e128.	0.5	0
111	Clesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models. <i>Clinical Cancer Research</i> , 2017, 23, 6661-6672.	3.2	110
112	Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. <i>Cancer Research</i> , 2017, 77, 5419-5427.	0.4	92
113	Evolution and clinical impact of co-occurring genetic alterations in advanced-stage <i>EGFR</i> -mutant lung cancers. <i>Nature Genetics</i> , 2017, 49, 1693-1704.	9.4	423
114	Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. <i>Cancer Research</i> , 2017, 77, 4238-4246.	0.4	95
115	Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5687-5695.	3.2	170
116	Costs of Diagnostic Assessment for Lung Cancer: A Medicare Claims Analysis. <i>Clinical Lung Cancer</i> , 2017, 18, e27-e34.	1.1	77
117	Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden. <i>Kidney Cancer</i> , 2017, 1, 65-70.	0.2	36
118	Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer—Transformed <i>EGFR</i> Mutant Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-7.	1.5	8
119	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0183949.	1.1	25
120	Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA—Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	1.5	31
121	Abstract 5684: NSABP FC-7 correlative study: <i>HER2</i> amplification (amp) in circulating cell-free DNA (cfDNA) in metastatic colorectal cancer (mCRC) resistant to anti- <i>EGFR</i> therapy (tx). , 2017, , .		2
122	Abstract 5692: Cross-platform detection and quantification of actionable mutations in cell-free DNA shows high concordance and correlation between next-generation sequencing and droplet digital PCR. , 2017, , .		4
123	Abstract CT011: Circulating tumor DNA (ctDNA) sequencing for <i>HER2</i> mutation (<i>HER2</i> mut) screening and response monitoring to neratinib in metastatic breast cancer (MBC). , 2017, , .		3
124	Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1514-1514.	0.8	3
125	Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4534-4534.	0.8	2
126	<i>MET</i> amplification (amp) as a resistance mechanism to osimertinib.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9020-9020.	0.8	45

#	ARTICLE	IF	CITATIONS
127	Abstract 1772:PIK3CAC2 domain deletions hyperactivate PI3K, generate oncogene dependence and are exquisitely sensitive to PI3KĪ inhibitors. , 2017, , .		0
128	Abstract 5394: The clinical impact of multiplex ctDNA gene analysis in lung cancer. , 2017, , .		0
129	Abstract 1009: Comprehensive ctDNA sequencing reveals mechanisms of resistance to rociletinib in EGFR T790M-mutated NSCLC. Cancer Research, 2017, 77, 1009-1009.	0.4	1
130	Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget, 2016, 7, 9707-9717.	0.8	123
131	Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget, 2016, 7, 66880-66891.	0.8	54
132	Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR -Mutant Lung Cancer. Journal of Thoracic Oncology, 2016, 11, e95-e97.	0.5	10
133	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i>V600E Mutation. Cancer Discovery, 2016, 6, 1352-1365.	7.7	192
134	A Genomic Alternative to Identify Medullary Thyroid Cancer Preoperatively in Thyroid Nodules with Indeterminate Cytology. Thyroid, 2016, 26, 785-793.	2.4	26
135	Abstract 4343: Comparison of over 10,000 clinical NGS circulating tumor DNA profiles to tissue-derived genomic compendia. , 2016, , .		0
136	Abstract 172: Managing metastatic breast cancer via serial monitoring with circulating cell-free tumor DNA next generation sequencing testing. , 2016, , .		0
137	Abstract 491: Salvage MET amplification detection and therapy through cell-free DNA NGS in a progressing lung cancer patient. , 2016, , .		0
138	Abstract 2240: A case series of ERBB2 indel driver mutations in non-small cell lung cancer identified by cell-free circulating tumor DNA NGS. , 2016, , .		0
139	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget, 2015, 6, 40360-40369.	0.8	85
140	Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS ONE, 2015, 10, e0140712.	1.1	580
141	Abstract 2403: Biopsy-free comprehensive tumor profiling of 1,000+ consecutive cancer patients using CLIA-certified commercial test and its clinical utility. , 2015, , .		1
142	MACHINE LEARNING FROM CONCEPT TO CLINIC: RELIABLE DETECTION OF BRAF V600E DNA MUTATIONS IN THYROID NODULES USING HIGH-DIMENSIONAL RNA EXPRESSION DATA. , 2014, , .		12
143	Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. Surgery, 2013, 154, 1420-1427.	1.0	190
144	Does Addition of <i>BRAF</i>V600E Mutation Testing Modify Sensitivity or Specificity of the Afirma Gene Expression Classifier in Cytologically Indeterminate Thyroid Nodules?. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E761-E768.	1.8	61

#	ARTICLE	IF	CITATIONS
145	A Prospective Assessment Defining the Limitations of Thyroid Nodule Pathologic Evaluation. <i>Annals of Internal Medicine</i> , 2013, 159, 325.	2.0	188
146	Use of the Afirma® Gene Expression Classifier for Preoperative Identification of Benign Thyroid Nodules with Indeterminate Fine Needle Aspiration Cytopathology. <i>PLOS Currents</i> , 2013, 5, .	1.4	9
147	Analytical Performance Verification of a Molecular Diagnostic for Cytology-Indeterminate Thyroid Nodules. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E2297-E2306.	1.8	57
148	The Impact of Benign Gene Expression Classifier Test Results on the Endocrinologist's Patient Decision to Operate on Patients with Thyroid Nodules with Indeterminate Fine-Needle Aspiration Cytopathology. <i>Thyroid</i> , 2012, 22, 996-1001.	2.4	140
149	Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology. <i>New England Journal of Medicine</i> , 2012, 367, 705-715.	13.9	1,054
150	A Large Multicenter Correlation Study of Thyroid Nodule Cytopathology and Histopathology. <i>Thyroid</i> , 2011, 21, 243-251.	2.4	309
151	Molecular Classification of Thyroid Nodules Using High-Dimensionality Genomic Data. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 5296-5304.	1.8	252
152	The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia. <i>Journal of the American College of Cardiology</i> , 2006, 48, 396-401.	1.2	136
153	Lipoprotein-Associated Phospholipase A 2 : Review and Recommendation of a Clinical Cut Point for Adults. <i>Preventive Cardiology</i> , 2006, 9, 138-143.	1.1	44